A Double-Blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Dose of ETI-204 in Adult Volunteers
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Obiltoxaximab (Primary)
- Indications Anthrax; Respiratory tract infections
- Focus Adverse reactions; Registrational
- Sponsors EluSys Therapeutics
- 14 Sep 2016 According to an Elusys Therapeutics media release, results from this study are published online at Clinical Therapeutics.
- 24 Aug 2016 Results assessing safety, immunogenicity, and pharmacokinetics of this and other four studies published in the Clinical Therapeutics
- 21 Mar 2016 According to Elusys media release, the U.S. Food and Drug Administration (FDA) has approved ANTHIM (obiltoxaximab) Injection, the company's monoclonal antibody (mAb) anthrax antitoxin.